IPHA vs. PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, STOK, SANA, and MRVI
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.
Innate Pharma vs. Its Competitors
Innate Pharma (NASDAQ:IPHA) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.
Innate Pharma has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%.
Innate Pharma has higher earnings, but lower revenue than Phathom Pharmaceuticals.
In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Innate Pharma's average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Innate Pharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
Innate Pharma currently has a consensus price target of $11.00, suggesting a potential upside of 528.57%. Phathom Pharmaceuticals has a consensus price target of $17.50, suggesting a potential upside of 94.01%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than Phathom Pharmaceuticals.
Summary
Innate Pharma beats Phathom Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:IPHA) was last updated on 7/9/2025 by MarketBeat.com Staff
Free IPHA Stock Alerts